Jianwei Xu1, Zhe Cao, Wenjing Liu, Lei You, Li Zhou, Chunyou Wang, Wenhui Lou, Bei Sun, Yi Miao, Xubao Liu, Taiping Zhang, Yupei Zhao. 1. *Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China†Pancreatic Disease Institute, Department of General Surgery, Wuhan Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China‡Departments of Pancreatic Surgery, Zhong Shan Hospital, Fudan University, Shanghai, China§Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, Harbin Medical University, Harbin, China¶Department of General Surgery, The First Affiliated Hospital, Nanjing Medical University, Nanjing, China||Department of Hepatopancreatobiliary Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Abstract
OBJECTIVES: To identify plasma microRNA (miRNA) markers of pancreatic cancer (PC). BACKGROUND: Accurate pretreatment diagnosis of PC remains challenging, whether plasma miRNAs could be used as biomarkers in PC remains unknown. METHODS: In this multiphase multicenter study, peripheral blood samples were obtained preoperatively in 3 phases: the discovery phase [7 patients with PC, 6 patients with chronic pancreatitis (CP), and 5 healthy volunteers (N)], the preliminary validation phase (29 patients with PC, 16 patients with CP, and 31 N), and the large sample validation phase (156 patients with PC, 65 N, 57 patients with CP, 27 patients with pancreatic neuroendocrine tumors, and 58 patients with other pancreatic tumors). The diagnostic values of the miRNAs were assessed and compared with cancer antigen 19-9 (CA19-9). RESULTS: The discovery phase demonstrated that 29 miRNAs were dysregulated in the patients with PC compared with the controls. In the preliminary validation phase, 13 miRNAs were shown to be dysregulated in the patients with PC and were selected for validation in a multicenter trial. MiR-486-5p exhibited diagnostic value in discriminating patients with PC from normal subjects or patients with CP, with area under the curve values of 0.861 and 0.707, respectively. MiR-938 exhibited diagnostic value in differentiating patients with PC from those with CP, pancreatic neuroendocrine tumors, and patients with other pancreatic tumors, with area under the curve values of 0.693, 0.660, and 0.618, respectively. In addition, we demonstrated that the value of miR-486-5p in discriminating patients with PC from normal subjects or patients with CP was comparable with that of CA19-9 (P = 0.602 and P = 0.230). CONCLUSIONS: This study identified several plasma miRNAs potentially suitable for distinguishing patients with PC from normal subjects or patients with other pancreatic tumors.
OBJECTIVES: To identify plasma microRNA (miRNA) markers of pancreatic cancer (PC). BACKGROUND: Accurate pretreatment diagnosis of PC remains challenging, whether plasma miRNAs could be used as biomarkers in PC remains unknown. METHODS: In this multiphase multicenter study, peripheral blood samples were obtained preoperatively in 3 phases: the discovery phase [7 patients with PC, 6 patients with chronic pancreatitis (CP), and 5 healthy volunteers (N)], the preliminary validation phase (29 patients with PC, 16 patients with CP, and 31 N), and the large sample validation phase (156 patients with PC, 65 N, 57 patients with CP, 27 patients with pancreatic neuroendocrine tumors, and 58 patients with other pancreatic tumors). The diagnostic values of the miRNAs were assessed and compared with cancer antigen 19-9 (CA19-9). RESULTS: The discovery phase demonstrated that 29 miRNAs were dysregulated in the patients with PC compared with the controls. In the preliminary validation phase, 13 miRNAs were shown to be dysregulated in the patients with PC and were selected for validation in a multicenter trial. MiR-486-5p exhibited diagnostic value in discriminating patients with PC from normal subjects or patients with CP, with area under the curve values of 0.861 and 0.707, respectively. MiR-938 exhibited diagnostic value in differentiating patients with PC from those with CP, pancreatic neuroendocrine tumors, and patients with other pancreatic tumors, with area under the curve values of 0.693, 0.660, and 0.618, respectively. In addition, we demonstrated that the value of miR-486-5p in discriminating patients with PC from normal subjects or patients with CP was comparable with that of CA19-9 (P = 0.602 and P = 0.230). CONCLUSIONS: This study identified several plasma miRNAs potentially suitable for distinguishing patients with PC from normal subjects or patients with other pancreatic tumors.
Authors: Jessica L Petrick; Ruth M Pfeiffer; Linda M Liao; Christian C Abnet; Xiaolin Wu; Marilie D Gammon; Thomas L Vaughan; Michael B Cook Journal: Dig Dis Sci Date: 2021-01-06 Impact factor: 3.199
Authors: Eric J Duell; Leila Lujan-Barroso; Núria Sala; Samantha Deitz McElyea; Kim Overvad; Anne Tjonneland; Anja Olsen; Elisabete Weiderpass; Lill-Tove Busund; Line Moi; David Muller; Paolo Vineis; Dagfinn Aune; Giuseppe Matullo; Alessio Naccarati; Salvatore Panico; Giovanna Tagliabue; Rosario Tumino; Domenico Palli; Rudolf Kaaks; Verena A Katzke; Heiner Boeing; H B As Bueno-de-Mesquita; Petra H Peeters; Antonia Trichopoulou; Pagona Lagiou; Anastasia Kotanidou; Ruth C Travis; Nick Wareham; Kay-Tee Khaw; Jose Ramon Quiros; Miguel Rodríguez-Barranco; Miren Dorronsoro; María-Dolores Chirlaque; Eva Ardanaz; Gianluca Severi; Marie-Christine Boutron-Ruault; Vinciane Rebours; Paul Brennan; Marc Gunter; Ghislaine Scelo; Greg Cote; Stuart Sherman; Murray Korc Journal: Int J Cancer Date: 2017-06-12 Impact factor: 7.396
Authors: Hanne Due; Pernille Svendsen; Julie Støve Bødker; Alexander Schmitz; Martin Bøgsted; Hans Erik Johnsen; Tarec Christoffer El-Galaly; Anne Stidsholt Roug; Karen Dybkær Journal: Biomed Res Int Date: 2016-05-16 Impact factor: 3.411